Pharmacogenomics of paclitaxel - PubMed (original) (raw)
Review
Pharmacogenomics of paclitaxel
Cristina Rodríguez-Antona. Pharmacogenomics. 2010 May.
Abstract
The microtubule-stabilizing drug paclitaxel is a cytotoxic agent widely used for the treatment of a variety of tumor types. Since its introduction to the clinic, modifications to the administration schedule and treatments for hypersensitivity reactions and neutropenia have significantly improved paclitaxel therapy. On the other hand, severe neurotoxicity and lack of response are still clinical challenges. During the last decade a deeper knowledge of paclitaxel pharmacokinetics and pharmacodynamics has been achieved, together with an in-depth characterization of genes involved in its elimination and therapeutic response. Pharmacogenetic studies aimed at the identification of paclitaxel outcome biomarkers have been performed, however, further efforts will be required to successfully integrate these and future results to provide the basis for personalized paclitaxel therapy.
Similar articles
- Germline pharmacogenetics of paclitaxel for cancer treatment.
Hertz DL. Hertz DL. Pharmacogenomics. 2013 Jul;14(9):1065-84. doi: 10.2217/pgs.13.90. Pharmacogenomics. 2013. PMID: 23837481 Review. - Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel.
Steed H, Sawyer MB. Steed H, et al. Pharmacogenomics. 2007 Jul;8(7):803-15. doi: 10.2217/14622416.8.7.803. Pharmacogenomics. 2007. PMID: 17638515 - Paclitaxel: a new antimitotic chemotherapeutic agent.
Gotaskie GE, Andreassi BF. Gotaskie GE, et al. Cancer Pract. 1994 Jan-Feb;2(1):27-33. Cancer Pract. 1994. PMID: 7914453 Review. - The scientific rationale for developing taxoids.
Aapro M. Aapro M. Anticancer Drugs. 1996 Aug;7 Suppl 2:33-6. Anticancer Drugs. 1996. PMID: 8862709 Review. - [Paclitaxel (taxol): a review of its antitumor activity and toxicity in clinical studies].
Yamazaki S, Sekine I, Saijo N. Yamazaki S, et al. Gan To Kagaku Ryoho. 1998 Mar;25(4):605-15. Gan To Kagaku Ryoho. 1998. PMID: 9530372 Review. Japanese.
Cited by
- Rates of paclitaxel hypersensitivity reactions using a modified Markman's infusion protocol as primary prophylaxis.
Symons R, Heath F, Duggan J, Bui KT, Byun L, Friedlander M, Lee YC. Symons R, et al. Support Care Cancer. 2024 Apr 17;32(5):292. doi: 10.1007/s00520-024-08460-z. Support Care Cancer. 2024. PMID: 38632132 Free PMC article. - Strategic and Innovative Roles of lncRNAs Regulated by Naturally-derived Small Molecules in Cancer Therapy.
Alkan AH, Ensoy M, Cansaran-Duman D. Alkan AH, et al. Curr Med Chem. 2024;31(40):6672-6691. doi: 10.2174/0109298673264372230919102758. Curr Med Chem. 2024. PMID: 37921177 Review. - Anticancer Effect of Spices Used in Mediterranean Diet: Preventive and Therapeutic Potentials.
Talib WH, AlHur MJ, Al Naimat S, Ahmad RE, Al-Yasari AH, Al-Dalaeen A, Thiab S, Mahmod AI. Talib WH, et al. Front Nutr. 2022 Jun 14;9:905658. doi: 10.3389/fnut.2022.905658. eCollection 2022. Front Nutr. 2022. PMID: 35774546 Free PMC article. Review. - A Bayesian Network Meta-Analysis for Identifying the Optimal Taxane-Based Chemotherapy Regimens for Treating Gastric Cancer.
Zhang D, Wu JR, Duan XJ, Wang KH, Zhao Y, Ni MW, Liu SY, Zhang XM, Zhang B. Zhang D, et al. Front Pharmacol. 2019 Jul 5;10:717. doi: 10.3389/fphar.2019.00717. eCollection 2019. Front Pharmacol. 2019. PMID: 31333452 Free PMC article. - Genome-Wide Study of Response to Platinum, Taxane, and Combination Therapy in Ovarian Cancer: In vitro Phenotypes, Inherited Variation, and Disease Recurrence.
Fridley BL, Ghosh TM, Wang A, Raghavan R, Dai J, Goode EL, Lamba JK. Fridley BL, et al. Front Genet. 2016 Mar 22;7:37. doi: 10.3389/fgene.2016.00037. eCollection 2016. Front Genet. 2016. PMID: 27047539 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources